Repligen Corporation

Repligen Corporation, a for-profit manufacturer of bioprocessing and analytical laboratory equipment headquartered in Waltham, Massachusetts, supplies specialized filtration systems, spectrophotometers, and cell culture controllers to federal research agencies as a prime contractor on full-and-open purchase orders, with no SBA set-aside designations across its federal footprint. The company operates two named subsidiaries — C Technologies, Inc. and Spectrum Lifesciences, LLC — both manufacturers of goods.

Repligen's capability portfolio centers on tangential flow filtration (TFF) systems, spectrophotometric analysis equipment, and bioreactor control systems used in vaccine development, monoclonal antibody production, and bioprocess development. Recent representative work includes a $169,186 firm-fixed-price purchase order from the USDA's Animal and Plant Health Inspection Service (awarded August 29, 2026) for a SoloVPE Plus spectrophotometer system with software licenses, installation qualification, and GMP-compliant training to analyze monoclonal antibody products at the Center for Veterinary Biologics laboratory in Ames, Iowa; a $174,560 purchase order from the FDA (awarded May 28, 2026) for XCell Lab Controllers and Accessories; and a $48,742 purchase order from the Defense Health Agency (awarded February 2, 2024) for a complete KR2i tangential flow filtration system and related equipment to support the Walter Reed Army Institute of Research's pilot bioproduction facility.

Customer concentration reflects biomedical research and development priorities. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response anchors 99% of combined potential value with a single $14.4 million award; the FDA holds the volume lead with five awards totaling $359 thousand in combined potential value. The National Institutes of Health (National Institute of Allergy and Infectious Diseases and National Cancer Institute), the Department of Agriculture's Veterinary Services, the Defense Health Agency, and the Navy's Bureau of Medicine and Surgery round out the active set. The vendor works predominantly through direct purchase orders rather than standing contract vehicles; the Multiple Award Schedule accounts for two task orders.

Repligen demonstrates steady federal engagement with eighteen total awards over the source window (2011 to present), though recent activity has accelerated — one award in 2021, one in 2022, one in 2023, four in 2024, and two in 2026. Combined potential value stands at $15.1 million against $15.5 million obligated. Awards cluster in biological product manufacturing (eight awards) and analytical laboratory instrument manufacturing (four awards), with the remainder in research and development support and laboratory services. Repligen subcontracts to Becton, Dickinson and Company on NIAID VRC operational task orders involving mRNA vaccine variant evaluation, supplying XCell Dual ATF2 systems and tangential flow filtration equipment, and to Leidos on a Bipartisan Infrastructure Law research support services task order. The vendor's prime footprint (83% of awards) operates on competitive federal procurement with no recurring set-aside posture.